The FDA has approved Yuvezzi as the first eye drop that combines two active ingredients – carbachol and brimonidine tartrate – to improve near vision without surgery.

Editor’s note: This is a developing story. Please check back soon for updates. Yuvezzi, an eye drop for the treatment of presbyopia, is now available in the U.S. According to a press release from Tenpoint Therapeutics, patients can fill prescriptions from eye care professionals for Yuvezzi (carbachol 2.75%/brimonidine tartrate 0.1% ophthalmic solution) through the company’s e-pharmacy partner, PHILRx, as well as local retail pharmacies. Yuvezzi is the first FDA-approved eye drop that uses two active ingredients to improve visual acuity and depth of focus: carbachol, which constricts the iris

Editor’s note: This is a developing story. Please check back soon for updates. Yuvezzi, an eye drop for the treatment of presbyopia, is now available in the U.S. According to a press release from Tenpoint Therapeutics, patients can fill prescriptions from eye care professionals for Yuvezzi (carbachol 2.75%/brimonidine tartrate 0.1% ophthalmic solution) through the company’s e-pharmacy partner, PHILRx, as well as local retail pharmacies. Yuvezzi is the first FDA-approved eye drop that uses two active ingredients to improve visual acuity and depth of focus: carbachol, which constricts the iris

Tenpoint Therapeutics’ Yuvezzi brings a combination approach to presbyopia compared to single mechanisms of action offered by once-daily eye drops from Orasis Pharmaceuticals, Lenz Therapeutics, and…

Lupin Limited and Tenpoint Therapeutics have announced a strategic partnership to market YUVEZZI™ in Europe, enhancing patient access to innovative eye care solutions.

Lupin Limited and Tenpoint Therapeutics have announced a strategic partnership aimed at marketing YUVEZZI™ in various European regions, enhancing access to presbyopia treatment for millions.

Lupin Limited and Tenpoint Therapeutics have announced a strategic partnership to market YUVEZZI™ in various European regions, enhancing access to innovative presbyopia treatment.

Lupin and Tenpoint Therapeutics have entered a strategic partnership to market YUVEZZI™ in various European regions, enhancing eye care access.

Lupin Limited and Tenpoint Therapeutics have entered a strategic partnership to bring YUVEZZI™ to key European markets, enhancing patient access.

-Lupin y Tenpoint Therapeutics anuncian una alianza estratégica para comercializar YUVEZZI™ en la Unión Europea, Reino Unido, Suiza, Noruega e Islandia Esta alianza demuestra un compromiso compartido para ampliar el acceso global al único colirio de doble acción para la corrección de la...

Ce partenariat témoigne d'un engagement commun à élargir l'accès mondial au seul collyre à double principe actif administré une fois par jour pour la correction de la presbytie, sur le segment en pleine croissance de la prise en charge de la presbytie MUMBAI, Inde, NAPLES, Floride,...

Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment MUMBAI, India and NAPLES, Fla. and WARREN, New Jersey and AMSTERDAM and LONDON, Aug. 20, 2026 /PRNewswire/...

Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment MUMBAI, India and NAPLES, Fla. and WARREN, New Jersey and AMSTERDAM and LONDON, Aug. 20, 2026 /PRNewswire/...

LONDON and WARREN, N.J.,—Tenpoint Therapeutics, Ltd., a global commercial-stage ophthalmic pharmaceutical company focused on developing treatments to improve

LONDON & WARREN, N.J.--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing

La FDA estadounidense acaba de aprobar Yuvezzi, un colirio de doble acción contra la presbicia que restaura la visión de cerca hasta 10 horas con solo una aplicación diaria...